ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo
August 16, 2018The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL). -
Kyowa Hakko Kirin announces results of Phase 3 trial of patients with Cutaneous T-cell Lymphoma
August 14, 2018MAVORIC study (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab in patients with cutaneous T-cell lymphoma (CTCL) have been published in Lancet Oncology.
Pharma Sources Insight January 2025
